HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US And Trading Neighbors Advocate Risk-Based, Science-Backed Cosmetics Regs

Executive Summary

As European industry’s concerns grow about “politicization” of regulatory programs, the United States-Mexico-Canada Agreement’s cosmetics annex directs regulatory authorities pursuing new rules to give due consideration to scientific and technical guidance documents developed through international collaboration.

You may also be interested in...



Ease Of Reaching Canada With Cosmetic/Drug Interface Products To Improve Under USMCA

Canada has agreed to end its practice of quarantining and retesting certain cosmetic-OTC drug products from the US, as part of a cosmetics-specific annex to the United States-Mexico-Canada Agreement. “There will be a very significant and immediate benefit to US exporters of OTC products to Canada,” a Personal Care Products Council exec said.

Ease Of Reaching Canada With Cosmetic/Drug Interface Products To Improve Under USMCA

Canada has agreed to end its practice of quarantining and retesting certain cosmetic-OTC drug products from the US, as part of a cosmetics-specific annex to the United States-Mexico-Canada Agreement. “There will be a very significant and immediate benefit to US exporters of OTC products to Canada,” a Personal Care Products Council exec said.

Endocrine Disruptors, The European Green Deal And The Politicization Of EU Chemical Programs

John Chave, director-general at Cosmetics Europe, says the European Commission’s plan for targeted assessment of 28 potential endocrine-disruptors in cosmetics – despite its conclusion in late 2018 that the current cosmetics regulatory framework adequately addresses endocrine-disruptor concerns – is symptomatic of a broad trend taking hold in Europe.

Related Content

Topics

UsernamePublicRestriction

Register

RS149686

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel